Darzalex 400mg Injection contains Daratumumab, a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells. It can be used alone or in conjunction with other medications to treat multiple myeloma. 

Brand Name: Darzalex

Composition: Daratumumab

Mechanism of Action:

Targeting CD38, a protein that is abundantly expressed on the surface of multiple myeloma cells, daratumumab is a CD38-directed cytolytic antibody. Daratumumab binds to CD38, which results in immune-mediated cytotoxicity, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC), and direct tumor cell death by apoptosis. Together, these systems eradicate cancer cells and slow the course of the illness.

Uses:

Multiple myeloma

Dosage and Administration:

Under the guidance of a medical practitioner with experience in cancer treatment, Darzalex is given as an intravenous (IV) infusion.

Side Effects:

·       Chills

·       Fever

·       Difficulty breathing

·       Fatigue

·       Nausea

·       Diarrhea

·       Constipation

·       Back pain

·       Cough

·       Decreased appetite

Safety Advise:

Lungs  

The safety of Darzalex Injection for individuals with lung issues is uncertain. Kindly speak with your healthcare provider.

Liver  

The safety of Darzalex Injection for individuals with liver issues is uncertain. Kindly speak with your healthcare provider.

  Kidney  

The safety of Darzalex Injection for individuals with Kidney issues is uncertain. Kindly speak with your healthcare provider.

Pregnancy  

Darzalex should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Darzalex while nursing is most likely dangerous. Kindly speak with your healthcare provider. 

Storage:

Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Keep the vial in the original carton to protect from light.

How to use this Medication?

In a medical context, a physician or nurse will administer daratumumab intravenously (into a vein) as a liquid (solution). The frequency of daratumumab administration will be determined by your doctor based on your body's reaction to the drug and any other medications that may be prescribed.

Your doctor may decide to temporarily or permanently discontinue your treatment, or reduce your daratumumab dosage. This is dependent on the adverse effects you encounter and how effectively the drug works for you. Throughout your daratumumab therapy, be careful to let your doctor know how you are feeling.

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Janssen Pharmaceuticals

Address: Johnson & Johnson Private Limited., 501 Arena Space, Behind Majas Bus Depot, Off Jogeshwari Vikhroli Link Road, Jogeshwari (E), Mumbai 400 060

Country of origin: United kingdome